Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of β-cell function and autoimmunity but improves glycemic control

Diabetes Care

Volumn 33, Issue 3, 2010, Pages 589-594

  Radtke, Maria Anita ^a,b   Nermoen, Ingrid ^c   Kollind, Magnus ^d   Skeie, Svein ^e   Sørheim, Jan Inge ^f   Svartberg, Johan ^g,h   Hals, Ingrid ^a   Moen, Torolf ^a   Dørflinger, Gry Høst ^a   Grill, Valdemar ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d Levanger Hospital   (Norway)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^h UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDIABETIC AGENT; ANTIGEN; C PEPTIDE; DIAZOXIDE; GABAPENTIN; GLUCOCORTICOID; GLUTAMATE DECARBOXYLASE 65; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISLET ANTIGEN 2; ISOPHANE INSULIN; NICOTINE; ORAL CONTRACEPTIVE AGENT; PROTON PUMP INHIBITOR; SHORT ACTING INSULIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; BEDTIME DOSAGE; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; FEMALE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MALE; METABOLIC REGULATION; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SLEEP DISORDER;

ADULT; ANTIHYPERTENSIVE AGENTS; AUTOIMMUNITY; BLOOD GLUCOSE; BODY WEIGHT; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DIAZOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; MALE; PLACEBOS; TIME FACTORS;

EID: 77649267697     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1436     Document Type: Article

References (22)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
2. Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: a randomized, controlled trial. Ann Intern Med 1998;128:517-523
3. Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988;37:1574-1582
4. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769
5. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352: 2598-2608
6. Trube G, Rorsman P, Ohno-Shosaku T. Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells. Pflugers Arch 1986;407:493-499
7. Björk E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996;45:1427-1430
8. Ortqvist E, Bjork E, Wallensteen M, Ludvigsson J, Aman J, Johansson C, Forsander G, Lindgren F, Berglund L, Bengtsson M, Berne C, Persson B, Karlsson FA. Temporary preservation of β-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004; 27:2191-2197
9. Qvigstad E, Kollind M, Grill V. Nine weeks of bedtime diazoxide is well tolerated and improves beta-cell function in subjects with type 2 diabetes. Diabet Med 2004;21:73-76
10. Radtke M, Kollind M, Qvigstad E, Grill V. Twelve weeks' treatment with diazoxide without insulin supplementation in type 2 diabetes is feasible but does not improve insulin secretion. Diabet Med 2007;24: 172-177
11. Karlsson FA, Bjork E. Beta-cell rest: a strategy for the prevention of autoimmune diabetes. Autoimmunity 1997;26: 117-122
12. Maedler K, Storling J, Sturis J, Zuellig RA, Spinas GA, Arkhammar PO, Mandrup-Poulsen T, Donath MY. Glucose- and interleukin-1β-induced β-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004;53:1706-1713
13. Sgouroudis E, Piccirillo CA. Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease. Diabetes Metab Res Rev 2009;25:208-218
14. Jonson CO, Pihl M, Nyholm C, Cilio CM, Ludvigsson J, Faresjo M. Regulatory T cell-associated activity in photopheresisinduced immune tolerance in recent onset type 1 diabetes children. Clin Exp Immunol 2008;153:174-181
15. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911
16. Gjessing HJ, Damsgaard EM, Matzen LE, Froland A, Faber OK. Reproducibility of β-cell function estimates in non-insulindependent diabetes mellitus. Diabetes Care 1987;10:558-562
17. Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003;52:1059-1065
18. Alemzadeh R, Slonim AE, Zdanowicz MM, Maturo J. Modification of insulin resistance by diazoxide in obese Zucker rats. Endocrinology 1993;133:705-712
19. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264
20. Alemzadeh R, Holshouser S. Effect of diazoxide on brain capillary insulin receptor binding and food intake in hyperphagic obese Zucker rats. Endocrinology 1999; 140:3197-3202
21. van Boekel G, Loves S, van SA, Ruinemans-Koerts J, Rijnders T, de Boer H. Weight loss in obese men by caloric restriction and high-dose diazoxide-mediated insulin suppression. Diabetes Obes Metab 2008;10:1195-1203
22. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, Haller M, Rockell J, Gottlieb P, Clare-Salzler M, Atkinson M. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007;56:604-612